These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39239161)

  • 21. High rates of unfavourable TB treatment outcomes observed in Madang Province, Papua New Guinea.
    Toua W; Lape V; Bolnga JW; Daimen M; Kelebi T; Vaccher S; Greig J
    Public Health Action; 2024 Sep; 14(3):105-111. PubMed ID: 39239162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss to follow-up among patients diagnosed with spinal tuberculosis at a tertiary hospital in Western Cape Province, South Africa: A retrospective cohort study.
    Mann TN; Davis JH; Dyers R
    S Afr Med J; 2020 Mar; 110(4):284-290. PubMed ID: 32657739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
    Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with loss to follow-up among TB patients in rural Papua New Guinea.
    Umo I; Kulai M; Commons RJ
    Public Health Action; 2021 Dec; 11(4):186-190. PubMed ID: 34956846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Adamashvili N; Baliashvili D; Kuchukhidze G; Salindri AD; Kempker RR; Blumberg HM; Lomtadze N; Avaliani Z; Magee MJ
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):326-333. PubMed ID: 35351237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea.
    Bainomugisa A; Lavu E; Pandey S; Majumdar S; Banamu J; Coulter C; Marais B; Coin L; Graham SM; du Cros P
    BMC Infect Dis; 2022 May; 22(1):437. PubMed ID: 35524232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 32. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.
    Suryawanshi SL; Shewade HD; Nagaraja SB; Nair SA; Parmar M
    Public Health Action; 2017 Jun; 7(2):116-122. PubMed ID: 28695084
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of loss to follow-up among adult tuberculosis patients in Southern Ethiopia: a retrospective follow-up study.
    Watumo D; Mengesha MM; Gobena T; Gebremichael MA; Jerene D
    BMC Public Health; 2022 May; 22(1):976. PubMed ID: 35568853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
    BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What happened to patients with RMP-resistant/MDR-TB in Zambia reported as lost to follow-up from 2011 to 2014?
    Kasapo CC; Chimzizi R; Simwanza SC; Mzyece J; Chizema E; Mariandyshev A; Lee HY; Harries AD; Kapata N
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):887-893. PubMed ID: 28786797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.
    Baliashvili D; Blumberg HM; Gandhi NR; Averhoff F; Benkeser D; Shadaker S; Gvinjilia L; Turdziladze A; Tukvadze N; Chincharauli M; Butsashvili M; Sharvadze L; Tsertsvadze T; Zarkua J; Kempker RR
    PLoS Med; 2023 May; 20(5):e1004121. PubMed ID: 37141386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq.
    Tesfahun HM; Al-Salihi L; Abdulkareem Al-Ani N; Mankhi AA; Mohammed A; Lim CAE; Al-Hilfi RA; Jouego CG; Decroo T; Moussally K; Ferlazzo G; Isaakidis P
    PLoS One; 2024; 19(1):e0296952. PubMed ID: 38241233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emergency response to multidrug-resistant tuberculosis in Daru, Western Province, Papua New Guinea, 2014-2017.
    Morris L; Hiasihri S; Chan G; Honjepari A; Tugo O; Taune M; Aia P; Dakulala P; Majumdar SS
    Public Health Action; 2019 Sep; 9(Suppl 1):S4-S11. PubMed ID: 31580333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.